Approval · Notice of Compliance 33233 · 2024
M-RIZATRIPTAN: Notice of Compliance 33233
Issued May 16, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33233
- Date
- May 16, 2024
- Company
- Mantra Pharma Inc.Brossard, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Manufacturers
- Canadian reference product
- MAXALT
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| M-RIZATRIPTAN | 02547708 | Approved |
| M-RIZATRIPTAN | 02547716 | Marketed |
Medicinal ingredients
- RIZATRIPTAN 5 MG per TAB
- RIZATRIPTAN 10 MG per TAB